Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies

Swetha R. Kanduri1, Wisit Cheungpasitporn2, Charat Thongprayoon2, Tananchai Petnak3,4, Yi Lin5, Karthik Kovvuru1, Sandhya Manohar2, Kianoush Kashani2,4 and Sandra M. Herrmann2

1Department of Medicine, Ochsner Medical Center, New Orleans, Louisiana, USA; 2Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA; 3Division of Pulmonary and Pulmonary Critical Care Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 4Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA; and 5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Correspondence: Sandra M. Herrmann, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. E-mail: herrmann.sandra@mayo.edu

Received 12 December 2020; revised 2 February 2021; accepted 8 February 2021; published online 17 February 2021

Kidney Int Rep (2021) 6, 1416–1422; https://doi.org/10.1016/j.ekir.2021.02.013
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Immunotherapy has grown significantly in the management of hematological and solid organ tumors. In-depth knowledge of T-cell pathways has led to the development of adoptive cell transfer techniques and subsequent evolution of chimeric antigen receptor T-cell (CAR-T) therapies.1 CAR-T cells are biologically engineered cells with a CAR receptor that recognizes a tumor antigen. T-cell receptors are equipped with extracellular domain and variable costimulatory domains yielding divergent T-cell response.2 Along with their utility among refractory B cell lymphomas, adult diffuse large B-cell lymphoma (DLBCL), and pediatric acute lymphoblastic leukemia (ALL), CAR-T therapies are now being explored in the management of solid organ tumors and multiple myeloma.3

Cytokine release syndrome (CRS), macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH), and immune effector cell-associated neurotoxicity syndrome (ICANS) are among the most alarming complications of CAR-T cells.1 The incidence of acute kidney injury (AKI) reported in the literature among patients with CAR-T therapies varies from 5% to 33%.1–22 The mechanism of AKI in patients with CAR-T cell therapy is not completely understood. However, it is proposed that AKI could be secondary to inflammation associated with cytokine release, potentially leading to acute tubular injury.15 Even though high-grade CRS is associated with AKI,18 the correlation between severe AKI requiring renal replacement therapies (AKI-RRT) and high grades of CRS is not widely known. We conducted a current systematic review of literature and meta-analysis of articles reporting the incidence of AKI among patients receiving CAR-T therapies and the correlation between severity of CRS and AKI-RRT incidence.

MATERIALS AND METHODS

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)23 statement in conducting systematic review. EMBASE, Cochrane, and Ovid MEDLINE databases were systematically searched from database inception through May 2020. Full details are provided in the Supplementary Material.

RESULTS

A total of 481 potentially relevant articles were identified and screened. In all, 32 articles were assessed in detail, of which 22 cohort studies1–22 with 3376 patients (Table 1) were included in our systematic review (Figure 1).

Incidence of AKI Among Patients Treated With CAR-T Cell Therapies

Overall, the pooled estimated incidence of AKI among patients treated with CAR-T therapies was 18.6% (95% CI = 14.3%–23.8%, I2 = 77%) (Figure 2), and the pooled estimated incidence of AKI-RRT was 4.4% (95% CI 2.1%–8.9%, I2 = 61%) (Supplementary Figure S1).
Table 1. Main characteristics of studies included in this meta-analysis of AKI incidence and mortality among patients treated with CAR-T cell therapy

| Study       | Year   | Age            | Indications for CAR-T therapy | Total number of patients (n) | AKI definition | AKI incidence/severe AKI | Cause of AKI/ biopsy | CRS grading | Baseline GFR | CRS with AKI vs. CRS without AKI | Mortality |
|-------------|--------|----------------|-------------------------------|------------------------------|----------------|---------------------------|---------------------|--------------|-------------|---------------------------------|-----------|
| Sauter et al.  | 2014   | 61 yr (34–68 yr) DLBCL B-NHL | 6 Not defined | Overall AKI, 1/6 = 16.6% | NA | Non-severe CRS, 1/2 = 50% Severe (grade 4 CRS), 1/2 = 50% | NA | Overall CRS, 2/6 = 33.3% No AKI mortality defined | NA |
| Lee et al.  | 2014   | 5–27 yr (range) Refractory B- ALL, NHL | 21 Not defined | Overall AKI, 1/21 = 5% | NA | CRS grade 1, 8/16 = 50% CRS grade 2, 2/16 = 12.5% CRS grade 3, 3/16 = 18.75% CRS grade 4, 3/16 = 18.75% | NA | Overall CRS, 16/21 = 76% No AKI CRS defined | NA |
| Kochenderfer et al.  | 2015   | 49 yr (range 30–68 yr) DLBCL, CLL, B CELL lymphoma | 15 Not defined | Overall AKI, 1/15 = 7% | NA | NA | NA | Overall CRS, 15/21 = 76% No AKI defined | NA |
| Ali et al.  | 2016   | 50 yr (range not reported) MM | 12 Not defined | Overall AKI, 2/12 = 16.6% | NA | CRS grade 3 and 4, 2/4 = 50% | NA | Overall CRS, 4/12 = 33.3% | NA |
| Fitzgerald et al.  | 2017   | Median 11 yr (range 6–22 yr) B-ALL | 39 KDIGO | Overall AKI, 18/39 = 46% Stage 1, 9/39 = 23% Stage 2, 6/39 = 15% Stage 3, 3/39 = 8% None required RRT | NA | CRS grade 1, 2/39 = 6% CRS stage 2, 16/36 = 44.4% Grade 3, 7/36 = 19.4% Grade 4, 11/36 = 30.5% | NA | Overall CRS, 36/39 = 92% | NA |
| Locke et al.  | 2017   | 49 yr (range 29–68 yr) DLBCL | 7 Needing RRT | AKI needing RRT, 1/7 = 14% | NA | CRS grade 1 and 2, 5/6 = 83% CRS grade 3, 0 CRS grade 4, 1/6 = 17% | NA | Overall CRS, 5/7 = 86% with AKI, 1/6 = 16% 9-mo Overall mortality, 4/7 = 57% No AKI mortality defined | NA |
| Hay et al.  | 2017   | 54 y (median 20–73 yr) ALL CLL NHL | 133 Not defined | Overall AKI, 3/133 = 2.25% (AKI reported in only grade 4 CRS patients) AKI needing RRT, 1/133 = 0.75% | NA | CRS grade 1 = 3.82/93 = 89.3% CRS grade 2 = 0.75% 10/93 = 10.7% | NA | Overall CRS, 93/133 = 70% with AKI, 3/93 = 3% | NA |
| Maude et al.  | 2018   | 11 yr (3–23 yr) B- ALL | 75 Needing RRT | AKI needing RRT, 7/75 = 9% | NA | CRS grade 1 and 2, 23/58 = 40% CRS grade 3, 16/58 = 28% CRS grade 4, 19/58 = 32% | NA | Overall CRS, 58/75 = 77% with AKI, 7/75 = 12% Overall 12-mo mortality, 19/75 = 25% | NA |
Table 1. (Continued) Main characteristics of studies included in this meta-analysis of AKI incidence and mortality among patients treated with CAR-T cell therapy

| Study          | Year   | Age                    | Indications for CAR-T therapy | Total number of patients (n) | AKI definition | AKI incidence/ severe AKI | Cause of AKI/biopsy | CRS grading | Baseline GFR | CRS with AKI vs. CRS without AKI | Mortality                  |
|----------------|--------|------------------------|--------------------------------|-----------------------------|----------------|---------------------------|---------------------|--------------|--------------|---------------------------------|-----------------------------|
| Rives et al.   | 2018   | Two groups: 1) <18 yr  | B- ALL                         | <18 yr, n = 84              | Needing RRT | NA                        | NA                  | NA           | NA           | Overall CRS, 66/84 = 79%          | Overall mortality >30 days, |
|                |        | (median = 10 yr, range 3–17 yr) |                               | 18–25 yr, n = 20            | Needing RRT | NA                        | NA                  | NA           | NA           | AKI/RRT with CRS, 7/66 = 11%      | 21/84 = 25%                 |
|                |        | 2) 18–25 yr            |                                |                             |                |                           |                     |              |              | Overall CRS, 18/20 = 90%           | Overall mortality >30 days, |
|                |        |                        |                                |                             |                |                           |                     |              |              | AKI/RRT with CRS, 4/18 = 22%      | 8/20 = 40%                  |
| Hartsell et al.| 2019   | <25 yr (no range       | ALL, DLDCL, AML                | 40                          | Not defined   | Overall AKI, 7/40 = 17.5% | NA                  | NA           | NA           | Overall mortality in-hospital, 3/40 = 7.5% |                            |
|                |        | mentioned)             |                                |                             |                |                           |                     |              |              |                                 |                            |
| Hartsell et al.| 2019   | >18 yr (no range       | B Cell Lymphoma, MM, Follicular lymphoma, ALL | 735                | Not defined   | Overall AKI, 110/735 = 15% | NA                  | NA           | NA           | Overall AKI mortality, 30/735 = 4% |                            |
|                |        | mentioned)             |                                |                             |                |                           |                     |              |              |                                 |                            |
| Talleur et al. | 2019   | <21 yr (no range       | Refractory B-ALL               | 5                           | Grade 3 AKI   | Grade 3 AKI, 1/5 = 20%   | NA                  | Grade 1 CRS, 1/5 = 100% | NA           | Overall CRS, 1/5 = 20%            | NA                          |
|                |        | mentioned)             |                                |                             |                |                           |                     |              |              |                                 |                            |
| Myers et al.   | 2019   | 11 yr (range 1.4 –     | Refractory B-ALL               | 125                        | KDIGO         | Overall AKI, 26/125 (21.0%, 95% CI = 14.5 – 28.9), Severe AKI (KDIGO stage 2 and 3) 15 patients (12%, 95% CI = 7.3 – 19.1), 3 patients (2.4%, 95% CI = 0.7 – 7.3) required RRT. | Patients with CRS had a 4.9 times greater risk of developing AKI (95% CI = 2.4 – 9.9; P < 0.001) and a 10.3 times greater risk of developing severe AKI (95% CI = 3.1 – 43; P < 0.001) | NA                        | Overall CRS, 100/125 = 80%       | NA                          |
|                |        | 29.1 yr)               |                                |                             |                |                           |                     |              |              |                                 |                            |
| Metwally et al.| 2019   | Adults (age not        | DLBCL                          | N = 58                      | Rise in creatinine >0.3 above baseline | Overall AKI, 19/58 = 33% | NA                  | NA           | NA           | AKI mortality at 6 months, 47% compared to 15% in non-AKI patients (P = 0.008) |                            |
|                |        | defined)               |                                |                             |                |                           |                     |              |              |                                 |                            |
| Myers et al.   | 2019   | 12 yr (range 1.4 –     | ALL                            | Total N = 213, ICU         | Needing RRT   | AKI needing RRT among ICU-admitted patients, 4/213 = 1.9% | NA                  | NA           | NA           | Overall 30-day mortality, 2/213 = 1% |                            |
|                |        | 29.1 yr)               |                                | admission, n = 49           |                |                           |                     |              |              |                                 |                            |
| Harris et al.  | 2020   | >18 yr                 | DLBCL                          | 1570                       | Not defined   | Overall AKI, 247/1570 = 15.7% | NA                  | NA           | NA           | Overall mortality, 30/1570 = 1.5% (in-hospital mortality) No AKI mortality reported |                            |
| Study                  | Year  | Age                  | Indications for CAR-T therapy | Total number of patients (n) | AKI definition | AKI incidence/severe AKI | Cause of AKI/biopsy | CRS grading | Baseline GFR | CRS with AKI vs. CRS without AKI | Mortality |
|-----------------------|-------|----------------------|-------------------------------|-----------------------------|----------------|--------------------------|--------------------|-------------|--------------|---------------------------------|------------|
| Hiramatsu et al.      | 2020  | Range 5–24 yr        | B-ALL                         | 6                           | Needing RRT    | AKI needing RRT, 2/6 = 33% | NA                 | NA          | NA           | Overall CR = 83%                   | No AKI mortality defined |
| Gutgarts et al.       | 2020  | 63 yr (range 19–86 yr) | DLBCL, NHL                    | 46                          | KDIGO          | Overall AKI, 14/46 = 30%  | CRS, 11/14 = 79%   | CRS grade 1 and 2, 3/14 = 5% | Overall 37/46 = 80% (95% CI = 62–90%) | 30-day AKI mortality, 1/14 = 14% |
| Gupta et al.          | 2020  | 60 yr (mean age 60 ± 13 yr) | DLBCL                         | 78                          | KDIGO          | Overall AKI, 15/78 = 19%  | Decreased kidney perfusion, 8 = | CR grade 0, 12/66 = 18%  | Overall CR = 86% | Overall 6-month mortality, 11/78 = 14% |
| Valade                | 2020  | 56 yr (median 27–65 yr) | DLBCL, ALL                    | 41                          | AKI needing RRT | Overall AKI, 2/41 = 5%   | NA                 | NA          | NA           | Overall CR = 85%                   | No AKI mortality defined |
| Lee et al.            | 2020  | Mean age 60 yr (SD 18 yr) | DLBCL                         | 37                          | AKI ≥ 1.5-fold rise in sCr from baseline | Overall AKI, 2/37 = 5% | NA                 | NA          | NA           | Overall CR = 52%                   | Overall mortality, 5/37 = 14% |

AKI, acute kidney injury; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; B-NHL, B-cell non-Hodgkin’s lymphoma; CLL, chronic lymphoblastic leukemia; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; GFR, glomerular filtration rate; ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes; NA, not available; NHL, non-Hodgkin’s lymphoma; MM, multiple myeloma; RRT, renal replacement therapy; sCr, serum creatinine.
Incidence of AKI Among Adults

Subgroup analysis among adults treated with CAR-T therapies resulted in the pooled estimated incidence of AKI at 17.0% (95% CI = 12.8%–22.2%, I² = 73%) (Supplementary Figure S2), and the incidence of AKI-RRT was 2.9% (95% CI = 0.9%–9.4%, I² = 41%) (Supplementary Figure S3). Upon analyzing the results using Kidney Disease: Improving Global Outcomes (KDIGO) criteria, the overall incidence of AKI was 18.6% (95% CI 14.3–23.8%, I² = 77%).

![Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for study selection.](image)

![Figure 2. Incidence of acute kidney injury (AKI) among patients treated with chimeric antigen receptor T-cell (CAR-T) therapies. CI, confidence interval.](image)
(KDIGO) criteria, we report that the pooled estimated AKI incidence among adults was 24.1% (95% CI = 14.9%−36.5%, I^2 = 49%) (Supplementary Figure S4). The incidence of AKI among adults on CAR-T therapies was slightly higher by KDIGO criteria as compared to overall AKI incidence.

Incidence of AKI Among Pediatric and Young Adult Patients
Among pediatric and young adult patients, the pooled estimated incidence of AKI was 22.5% (95% CI = 11.1%−40.1%, I^2 = 79%) (Supplementary Figure S5) and AKI-RRT was 6.0% (95% CI = 2.2%−15.5%, I^2 = 72%) (Supplementary Figure S6). We noticed higher rates of AKI and AKI-RRT among pediatric and young adults than reported among adults. In addition, higher rates of AKI were noted among pediatric and young adults even when analyzed using KDIGO criteria, with an estimated incidence of 31.7% (95% CI = 12.7%−59.6%, I^2 = 89%) (Supplementary Figure S7).

Incidence of CRS Among Patients With CAR-T Therapies
Among patients on CAR-T therapies, the estimated CRS incidence in all included studies was 75.4% (95% CI = 66.6%−82.4%, I^2 = 71%) (Supplementary Figure S8). Upon analyzing the relationship between CRS severity and incidence of AKI-RRT, we found a strong correlation between them (slope = +0.0413, P = 0.01) (Supplementary Figure S9).

Publication Bias
Funnel plots (Supplementary Figures S10–S13) and Egger regression asymmetry tests were performed to evaluate for publication bias. We found no significant publication bias in the meta-analysis evaluating AKI incidence (P ≥ 0.05 for all analysis).

DISCUSSION
In the current era, the utility of CAR-T therapies has extended widely among patients with various cancers. In our study, the pooled incidence of any AKI among all patients with CAR-T therapies was 19%, and the incidence of AKI-RRT was 4%. Upon analyzing studies that defined AKI by KDIGO criteria, the pooled incidence of AKI among adults was slightly higher at 24%. This observation could be secondary to using a definition with a higher sensitivity in identifying patients with AKI. Interestingly, most patients experienced only mild AKI, with a rise in serum creatinine ≥0.3 mg/dl to 1.5 times baseline creatinine, and a smaller proportion of patients reached AKI stage 3 or AKI-RRT. Our findings are in concordance with the results of the largest published studies on AKI incidence among patients with CAR-T therapies.4,5,14, S18, S19

We found that the pooled incidence of CRS among patients with CAR-T therapies was 75%, which is in agreement with major published studies. S1,S3,S6–S9,S13,S17–S20 Our analysis reports a strong correlation between AKI-RRT incidence and severe CRS. In addition, our study indicated a higher incidence of AKI and AKI-RRT in the pediatric population than in older adults (22.5% vs. 17% and 6% vs. 2.9%, respectively). The current observation could be secondary to increased CRS incidence among the pediatric population as reported by Lee et al. and Maulde et al.S3,S8 The underlying mechanisms for a higher incidence of CRS among the pediatric population are unclear. However, it is hypothesized to be related to a higher dose, excessive tumor burden, and association of ALL with higher blast count leading to increased CRS risk,3 and, finally, immaturity of the immune system among pediatric patients and young adults.

Our study has several strengths. It is the first systematic review looking at the pooled incidence of AKI among adults and pediatric subgroups receiving CAR-T therapies and reporting a correlation between incidence of AKI-RRT and severe CRS. However, our systematic review also has a few limitations. We included a few retrospective cohort studies with smaller sample sizes that reported associations rather than a causal relationship between AKI incidence and CAR-T cell therapies. There is modest heterogeneity among various studies in defining AKI. In addition, we do not have data on baseline kidney function except for a few studiesS18,S19 that included patients with median and mean baseline GFR >60 ml/min per m^2 respectively.

In conclusion, we report that AKI incidence among patients with CAR-T therapies varies among pediatric and adult cohorts. We additionally report a strong correlation between the severity of CRS and AKI-RRT. As AKI-RRT is associated with higher mortality and morbidity, it would be helpful to undertake additional preventive strategies along with the addition of tocilizumab in patients at high risk for severe CRS to mitigate the risk of AKI. Future research on identifying models or biomarkers that could help to predict AKI among patients on CAR-T therapies and the impact of preventive measures on the incidence of AKI, AKI-RRT, and severe CRS is warranted.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
SMH is supported by K08 DK118120 from the National Institute of Diabetes and Digestive and Kidney Diseases
and by a Mary Kathryn and Michael B. Panitch Career Development Award.

AUTHOR CONTRIBUTIONS
SK, TP, and SM performed an independent literature search using search terms. WC, CT, and KK collected the data. SK, SH, and KK interpreted the data. SK, WC, CT, TP, YL, KK, SM, KK, and SH prepared the manuscript and approved the current version of the manuscript.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Supplementary Methods
Figure S1. Incidence of severe AKI or AKI-RRT among patients on CAR-T therapies.
Figure S2. Incidence of overall AKI among adults on CAR-T therapies.
Figure S3. Incidence of AKI-RRT among adults on CAR-T therapies.
Figure S4. Incidence of overall AKI (only KDIGO definition) among adults on CAR-T therapies.
Figure S5. Incidence of overall AKI among pediatric patients and young adults on CAR-T therapies.
Figure S6. Incidence of severe AKI-RRT among pediatric patients and young adults.
Figure S7. Incidence of overall AKI (only KDIGO definition) among pediatric patients and young adults.
Figure S8. Overall incidence of CRS among patients on CAR-T therapies.
Figure S9. Relation between CRS severity of incidence of AKI-RRT among patients on CAR-T therapies.
Figure S10. Funnel plot of adults with AKI on CAR-T therapies.
Figure S11. Funnel plot of adults with severe AKI-RRT on CAR-T therapies.
Figure S12. Funnel plot of pediatric patients and young adults with AKI on CAR-T therapies.
Figure S13. Funnel plot of pediatric and young adult patients with severe AKI-RRT on CAR-T therapies.

Supplementary References
REFERENCES
1. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30:157–167.
2. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–68.
3. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–1737.
4. Thongprayoon C, Hansrivijit P, Kovvuru K, et al. Diagnostics, risk factors, treatment and outcomes of acute kidney injury in a new paradigm. J Clin Med. 2020;9:1104.
5. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra225.